The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Introduction. The aim of this study was to compare the cost-effectiveness of continuous erythropoietin receptor activator (CERA) once monthly to epoetin beta (EpoB) thrice weekly to maintain haemoglobin (Hb) within the range 10.5–12 g/dL. Methods. Prospective cohort study and cost-effectiveness anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Maoujoud, Omar, Ahid, Samir, Dkhissi, Hocein, Oualim, Zouhair, Cherrah, Yahia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710935/
https://www.ncbi.nlm.nih.gov/pubmed/26843983
http://dx.doi.org/10.1155/2015/189404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710935/
https://www.ncbi.nlm.nih.gov/pubmed/26843983
http://dx.doi.org/10.1155/2015/189404

Ejemplares similares